Advantage Alpha Capital Partners LP Catalyst Pharmaceuticals, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 25,196 shares of CPRX stock, worth $575,476. This represents 0.12% of its overall portfolio holdings.
Number of Shares
25,196
Previous 37,320
32.49%
Holding current value
$575,476
Previous $578,000
13.49%
% of portfolio
0.12%
Previous 0.13%
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
332Shares Held
94.6MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$427 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$184 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$142 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$130 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$68.9 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.35B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...